Geode Capital Management’s Marker Therapeutics MRKR Stock Holding History

Geode Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$209K	Buy	160,910 +30,566	+23%	+$48.5K	﹤0.01%	3896
2025 Q4	$194K	Buy	130,344 +34,028	+35%	+$38.5K	﹤0.01%	3915
2025 Q3	$86K	Buy	96,316 +548	+0.6%	+$677	﹤0.01%	4166
2025 Q2	$147K	Buy	95,768 +7,099	+8%	+$9.11K	﹤0.01%	3967
2025 Q1	$109K	Buy	88,669 +12,989	+17%	+$23.8K	﹤0.01%	4008
2024 Q4	$235K	Buy	75,680 +4,119	+6%	+$14.6K	﹤0.01%	3851
2024 Q3	$202K	Buy	71,561 +3,319	+5%	+$13.1K	﹤0.01%	3897
2024 Q2	$371K	Buy	68,242 +1,189	+2%	+$5.05K	﹤0.01%	3678
2024 Q1	$288K	Buy	67,053 +7,006	+12%	+$30.6K	﹤0.01%	3810
2023 Q4	$330K	Hold	60,047	–	–	﹤0.01%	3762
2023 Q3	$276K	Buy	60,047 +2,296	+4%	+$12.8K	﹤0.01%	3849
2023 Q2	$179K	Hold	57,751	–	–	﹤0.01%	4093
2023 Q1	$41K	Sell	57,751 -3	-0%	-$7	﹤0.01%	4562
2022 Q4	$152K	Sell	57,754 -156	-0.3%	-$538	﹤0.01%	4228
2022 Q3	$213K	Hold	57,910	–	–	﹤0.01%	4178
2022 Q2	$191K	Hold	57,910	–	–	﹤0.01%	4294
2022 Q1	$254K	Buy	57,910 +2,340	+4%	+$13.4K	﹤0.01%	4261
2021 Q4	$528K	Sell	55,570 -5	-0%	-$66	﹤0.01%	4015
2021 Q3	$939K	Buy	55,575 +890	+2%	+$18.2K	﹤0.01%	3716
2021 Q2	$1.52M	Buy	54,685 +6,082	+13%	+$160K	﹤0.01%	3386
2021 Q1	$1.09M	Sell	48,603 -3,984	-8%	-$91.2K	﹤0.01%	3516
2020 Q4	$762K	Buy	52,587 +1,820	+4%	+$28.3K	﹤0.01%	3452
2020 Q3	$761K	Buy	50,767 +3,433	+7%	+$62.6K	﹤0.01%	3301
2020 Q2	$979K	Buy	47,334 +3,922	+9%	+$85.8K	﹤0.01%	3140
2020 Q1	$824K	Buy	43,412 +74	+0.2%	+$1.89K	﹤0.01%	3089
2019 Q4	$1.25M	Buy	43,338 +2,954	+7%	+$107K	﹤0.01%	3199
2019 Q3	$2.06M	Buy	40,384 +2,738	+7%	+$162K	﹤0.01%	2925
2019 Q2	$2.98M	Buy	37,646 +13,819	+58%	+$821K	﹤0.01%	2699
2019 Q1	$1.57M	Buy	23,827 +81	+0.3%	+$4.73K	﹤0.01%	2983
2018 Q4	$1.32M	Buy	23,746 +18,898	+390%	+$1.38M	﹤0.01%	2988
2018 Q3	$438K	Buy	4,848 +505	+12%	+$43.4K	﹤0.01%	3512
2018 Q2	$409K	Buy	+4,343	New	+$221K	﹤0.01%	3506

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management's MRKR Position: Q1 2026 in Review

Geode Capital Management increased its Marker Therapeutics (MRKR) stake by 23% in Q1 2026, buying an estimated $48.5K and bringing the position to 160,910 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #3896.

Geode Capital Management first reported a position in MRKR in Q2 2018 and has held it in 32 quarters since. The position peaked at $2.98M in Q2 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

Geode Capital Management held 160,910 shares of Marker Therapeutics worth $209K as of Q1 2026.
Geode Capital Management bought 30,566 Marker Therapeutics shares in Q1 2026, an estimated $48.5K.
Marker Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3896 holding.
Geode Capital Management first reported a position in Marker Therapeutics in Q2 2018 and has held it in 32 quarters since.
Geode Capital Management's Marker Therapeutics position peaked at $2.98M in Q2 2019.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.